Understanding the global epidemiology of paediatric multiple sclerosis represents a vital priority for neurology and child health worldwide. Although multiple sclerosis predominantly develops during adulthood, approximately three to five percent of all individuals experience their initial demyelinating event during childhood or adolescence. The Multiple Sclerosis International Federation (MSIF) Atlas of MS, third edition, offers pivotal insights into the worldwide prevalence and diagnostic patterns of this condition. Researchers analyzed comprehensive international surveillance records to establish updated epidemiological benchmarks and assess healthcare resource distribution. Consequently, these findings highlight critical disparities in specialist availability, diagnostic infrastructure, and registry tracking across different geographic and economic regions. By assessing how healthcare capacity influences disease ascertainment, clinicians and public health leaders can better understand the true global burden of paediatric demyelination.

Global Burden and Prevalence of Paediatric Multiple Sclerosis

The third edition of the MSIF Atlas of MS provides the most extensive assessment of paediatric multiple sclerosis across the globe. In this landmark analysis, investigators evaluated data collected between 2020 and 2022 from 53 countries spanning all World Health Organization regions and World Bank income categories. The international cohort captured 31,420 paediatric multiple sclerosis cases worldwide. Furthermore, the crude global prevalence was estimated at 2.53 per 100,000 children. After researchers adjusted the figures to minimize outlier distortion and reflect global income distribution, the worldwide adjusted prevalence was calculated at 1.48 per 100,000 children.

These figures confirm that paediatric-onset demyelinating disease is rare in the general paediatric population. However, this absolute caseload carries immense clinical and public health significance because young patients experience heightened inflammatory activity. Children frequently present with higher relapse rates during early disease stages compared to adult cohorts. Therefore, establishing precise epidemiological baselines is essential for designing healthcare services, funding national registries, and allocating specialized neurological resources effectively.

Socioeconomic Disparities and the Diagnostic Gradient

Significant disparities exist between high-income and lower-income nations regarding the documented prevalence of paediatric multiple sclerosis. Remarkably, only 24% of surveyed countries globally were able to report paediatric-specific epidemiological data, revealing substantial gaps in international surveillance. Among lower-income countries providing data, 67% reported low prevalence bands of fewer than 1.0 case per 100,000 children. In contrast, only 34% of higher-income countries fell into this lowest prevalence bracket.

Furthermore, 34% of higher-income nations documented high prevalence bands of 3.1 or more cases per 100,000 children. Conversely, only 7% of lower-income nations reached this diagnostic threshold. This striking variance does not merely reflect biological differences or latitudinal gradients. Instead, it reflects systemic diagnostic barriers within resource-constrained healthcare environments. Lower-income countries often face limited access to advanced neuroimaging, specialized immunology testing, and standardized surveillance registries. Consequently, young patients in underserved communities frequently face under-diagnosis or prolonged diagnostic delays that adversely affect clinical outcomes.

Child Neurologist Availability and Diagnostic Ascertainment

The local density of specialized medical professionals directly influences how efficiently healthcare systems identify paediatric central nervous system demyelination. The Atlas of MS study demonstrated a strong positive correlation between the per capita prevalence of child neurologists and reported paediatric multiple sclerosis prevalence bands. Regions with higher concentrations of child neurologists consistently reported higher prevalence rates.

Child neurologists play a central role in recognizing atypical presenting symptoms, differentiating inflammatory demyelination from infectious mimics, and applying established diagnostic criteria. In resource-limited regions, the severe shortage of specialized paediatric neurologists restricts case detection. As a result, children with demyelinating episodes may receive alternative diagnoses, such as acute disseminated encephalomyelitis or non-specific encephalitis. Expanding specialized paediatric neurology training programs and building regional referral networks are therefore critical priorities. Ultimately, strengthening the specialist workforce will enhance diagnostic accuracy and ensure timely intervention for affected children.

Clinical Spectrum and Phenotypic Nuances in Children

Paediatric multiple sclerosis exhibits unique biological and clinical characteristics that distinguish it from adult-onset disease. Nearly all children and adolescents present with a relapsing-remitting disease course, whereas primary progressive forms remain exceptionally uncommon in this population. However, younger children under 12 years of age frequently present with polysymptomatic onsets and encephalopathy, closely mimicking acute disseminated encephalomyelitis. In contrast, adolescents more commonly present with monosymptomatic deficits such as optic neuritis, sensory disturbances, or transverse myelitis.

Although paediatric patients generally show rapid initial recovery from individual relapses, their central nervous system lesion volume accumulates rapidly. High early relapse frequencies accelerate disease progression over time. Moreover, because the disease manifests during formative years of brain development, children face substantial risks of neurocognitive impairment, fatigue, and educational disruption. Clinicians must maintain high clinical vigilance and employ antibody testing to differentiate MS from myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and neuromyelitis optica spectrum disorder (NMOSD).

Therapeutic Advances and Modern Management Paradigms

The therapeutic landscape for paediatric multiple sclerosis has expanded considerably over the past decade. Early initiation of disease-modifying therapies (DMTs) is vital to reduce relapse frequency, prevent physical disability, and protect cognitive function. While injectable therapies such as interferon-beta and glatiramer acetate previously served as standard initial options, recent randomized clinical trials have established the safety and efficacy of oral and monoclonal antibody therapies in children.

Specifically, oral agents such as fingolimod and teriflunomide have received regulatory approval for paediatric use based on robust clinical trial data. Furthermore, clinicians increasingly utilize high-efficacy monoclonal antibodies, including ocrelizumab and natalizumab, for aggressive paediatric disease. Alongside pharmacological treatments, multidisciplinary care is essential. Healthcare teams must address comorbidities through physical rehabilitation, academic accommodations, psychological counseling, and vitamin D optimization. Early personalized treatment plans preserve long-term neurological integrity and enhance overall quality of life.

Implications for Global Health and Clinical Surveillance

The epidemiological findings from the Atlas of MS deliver clear directives for international medical societies and health authorities. Establishing standardized national and international registries is critical for monitoring long-term disease trajectories and evaluating treatment outcomes in real-world settings. Standardized data collection protocols will help eliminate reporting disparities between high-income and resource-limited regions.

Additionally, global health advocacy must focus on improving equitable access to essential neurodiagnostic tools and disease-modifying medications. International organizations must collaborate with local healthcare systems to deliver teleconsultation services, standardized clinical guidelines, and education for frontline paediatricians. By embedding child neurology expertise into broader health systems, countries can narrow the diagnostic gap. Ultimately, strengthening global surveillance will ensure that every child with multiple sclerosis receives timely, evidence-based medical care regardless of geography.

Frequently Asked Questions

What is the global prevalence of paediatric multiple sclerosis?

According to the MSIF Atlas of MS third edition, the crude global prevalence of paediatric multiple sclerosis is approximately 2.53 per 100,000 children. When adjusted for global income distribution and outlier distortion, the worldwide prevalence rate is estimated at 1.48 per 100,000 children.

How does paediatric multiple sclerosis differ clinically from adult-onset disease?

Paediatric multiple sclerosis almost exclusively presents with a relapsing-remitting course and features a higher early relapse rate than adult disease. Children recover faster from acute attacks but reach irreversible disability at a younger chronological age. Furthermore, younger children often present with encephalopathy and multifocal neurological symptoms.

Why are prevalence rates lower in resource-limited countries?

Lower prevalence rates in resource-limited countries primarily reflect under-diagnosis rather than true disease absence. These settings often experience severe shortages of child neurologists, restricted access to high-field magnetic resonance imaging, limited serological testing for mimics, and an absence of standardized national registries for paediatric neurological diseases.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Gombolay G et al. Worldwide epidemiology of paediatric multiple sclerosis: data from the Multiple Sclerosis International Federation Atlas of MS, third edition. J Neurol Neurosurg Psychiatry. 2025 Jul 16. doi: 10.1136/jnnp-2024-335175. PMID: 39848676.
2. Banwell B, Arnold DL, Tillema JM, et al. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol. 2023;22(1):75-88.
3. Chitnis T, Arnold DL, Banwell B, et al. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. N Engl J Med. 2018;379(11):1017-1027.